Dana-Farber Chief Scientific Officer, Kevin Haigis, PhD, elected as Fellow of the American Association for the Advancement of Science
Boston – Kevin Haigis, PhD, Chief Scientific Officer, Dana-Farber Cancer Institute, has been named Fellow of the American Association for the Advancement of Science (AAAS). Election as an AAAS Fellow is a distinguished lifetime honor bestowed upon AAAS members by their peers.
Credit: Dana-Farber Cancer Institute
Boston – Kevin Haigis, PhD, Chief Scientific Officer, Dana-Farber Cancer Institute, has been named Fellow of the American Association for the Advancement of Science (AAAS). Election as an AAAS Fellow is a distinguished lifetime honor bestowed upon AAAS members by their peers.
Haigis is recognized within Biological Sciences for his distinguished contributions to understanding the complex diversity of cellular dysregulation by different variants of RAS mutations and their consequences in pathophysiology and treatment.
Haigis has been a member of the Harvard Medical School faculty since 2007, currently as a Professor of Medicine. The Haigis laboratory combines computational and informatic approaches with experimental approaches in models to study the relationship between RAS signaling, colorectal cancer, and inflammation.
Haigis received his PhD from the University of Wisconsin in 2002 and continued training as a postdoctoral fellow in the laboratory of Tyler Jacks at MIT. He previously served as Director of Cancer Genetics at Beth Israel Deaconess Cancer before joining Dana-Farber. He is also an Associate Member of the Broad Institute of MIT and Harvard.
This year Haigis is among 502 scientists, engineers, and innovators elected across 24 AAAS disciplinary sections, as AAAS celebrates the 150th anniversary of the AAAS Fellows.
The tradition of AAAS Fellows began in 1874. This year’s AAAS Fellows will be celebrated at the annual Fellows Forum in Washington, D.C. on September 21, 2024.
About Dana-Farber Cancer Institute
Dana-Farber Cancer Institute is one of the world’s leading centers of cancer research and treatment. Dana-Farber’s mission is to reduce the burden of cancer through scientific inquiry, clinical care, education, community engagement, and advocacy. Dana-Farber is a federally designated Comprehensive Cancer Center and a teaching affiliate of Harvard Medical School.
We provide the latest treatments in cancer for adults through Dana-Farber Brigham Cancer Center and for children through Dana-Farber/Boston Children’s Cancer and Blood Disorders Center. Dana-Farber is the only hospital nationwide with a top 5 U.S. News & World Report Best Cancer Hospital ranking in both adult and pediatric care.
